Methylprednisolone hemisuccinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Methylprednisolone hemisuccinate
Accession Number
DB14644
Type
Small Molecule
Groups
Approved
Description

A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Structure
Thumb
Synonyms
  • Methylprednisolone hydrogen succinate
  • Methylprednisolone succinate
Product Ingredients
IngredientUNIICASInChI Key
Methylprednisolone sodium succinateLEC9GKY20K2375-03-3FQISKWAFAHGMGT-SGJOWKDISA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Solu-MedrolInjection, powder, lyophilized, for solution125 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-012017-01-16Us
Solu-MedrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution1 g/8mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution1 g/1mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousCardinal Health1959-04-022010-06-30Us
Solu-MedrolInjection, powder, for solution125 mg/1mLIntramuscular; IntravenousUNSPECIFIED2006-06-082006-06-08Us
Solu-medrolInjection, powder, for solution500 mg/1mLIntramuscular; IntravenousPhysicians Total Care, Inc.1959-04-022010-06-30Us
Solu-medrolInjection, powder, for solution125 mg/1mLIntramuscular; IntravenousSina Health Inc1959-04-02Not applicableUs
Solu-MedrolInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution500 mg/4mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1959-04-02Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-methapredInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01Us
A-methapredInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01Us
A-methapredInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2009-06-222013-05-01Us
A-methapredInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2009-07-142013-05-01Us
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution1 g/16mLIntramuscular; IntravenousSagent Pharmaceuticals2017-03-15Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousAmneal Biosciences Llc2016-11-11Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousBedford Pharmaceuticals2007-03-012009-06-30Us
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/1Intramuscular; IntravenousAuroMedics Pharma LLC2015-12-15Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousSagent Pharmaceuticals2017-03-15Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousBedford Pharmaceuticals2007-03-012009-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
5GMR90S4KN
CAS number
2921-57-5
Weight
Average: 474.55
Monoisotopic: 474.225368055
Chemical Formula
C26H34O8
InChI Key
IMBXEJJVJRTNOW-XYMSELFBSA-N
InChI
InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinMethylprednisolone hemisuccinate may increase the anticoagulant activities of (R)-warfarin.
(S)-WarfarinMethylprednisolone hemisuccinate may increase the anticoagulant activities of (S)-Warfarin.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Methylprednisolone hemisuccinate.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Methylprednisolone hemisuccinate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Methylprednisolone hemisuccinate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Methylprednisolone hemisuccinate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Methylprednisolone hemisuccinate.
1alpha,24S-Dihydroxyvitamin D2The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Methylprednisolone hemisuccinate.
2,4-thiazolidinedioneThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with 2,4-thiazolidinedione.
4-hydroxycoumarinMethylprednisolone hemisuccinate may increase the anticoagulant activities of 4-hydroxycoumarin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
16034
ChEBI
135765
ChEMBL
CHEMBL1201265
Wikipedia
Methylprednisolone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceNormal Physiology1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
1TerminatedNot AvailableDisseminated Sclerosis / Healthy Volunteers1
1Unknown StatusTreatmentOcular GVHD1
1, 2WithdrawnPreventionHearing Loss, Noise-Induced1
2Active Not RecruitingTreatmentLeukemias1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Postoperative Complications1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentBlood Cancers / Chronic Lymphocytic Leukaemia (CLL) / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / Non-Hodgkin's Lymphoma (NHL) / Smith-Magenis Syndrome1
2CompletedTreatmentLeukemia, Mast-Cell / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentMalignant Lymphomas1
2TerminatedTreatmentInsufficiency; Hepatic, Postoperative / Ischemic Reperfusion Injury / Neoplasms, Hepatic1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2WithdrawnTreatmentGraft Versus Host Disease, Acute / Intestinal Graft Versus Host Disease1
2, 3RecruitingTreatmentPneumonia, Bacterial1
3CompletedTreatmentSudden Deafness1
3Not Yet RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myeloid Leukemias1
4CompletedPreventionDelirium - Postoperative / Stress, Physiological1
4CompletedTreatmentAlopecia Totalis (AT) / Alopecia Universalis (AU) / Ophiasic Alopecia1
4CompletedTreatmentAsthma1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentNeoplasms, Lung1
4CompletedTreatmentSepsis1
4CompletedTreatmentViral Bronchiolitis1
4RecruitingTreatmentOrthopedic Surgeries1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/16mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/8mL
Injection, powder, for solutionIntracavernous; Intramuscular40 mg/1
Injection, powder, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/1mL
Injection, powder, for solutionIntramuscular; Intravenous125 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1mL
KitIntravenous2 g/30.6mL
Powder, for solutionIntravenous125 mg/1mL
Powder, for solutionIntramuscular; Intravenous; Rectal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0264 mg/mLALOGPS
logP2.43ALOGPS
logP1.83ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.66ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area138.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity123.09 m3·mol-1ChemAxon
Polarizability49.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]

Drug created on September 01, 2018 15:25 / Updated on November 02, 2019 04:23